Sepsis Bundles Are a Safety Floor, Not the Finish Line, Commentary Argues

Writing in Anesthesiology and Perioperative Science, a team of researchers proposes that sepsis bundles be understood as a standardized safety floor: a set of time-critical interventions that must never be delayed, followed by a continuous cycle of reassessment and adaptive adjustment tailored to each patient’s evolving condition.

The commentary, published on 26 October 2026 as an open-access piece, situates itself against the backdrop of the 2026 Surviving Sepsis Campaign guidelines, which retain rapid recognition, timely antimicrobial therapy, source-control assessment, initial hemodynamic stabilization, and basic organ support as key priorities. The authors are explicit that these measures should not be delayed. Their argument concerns what happens afterward. Even once the initial bundle is complete, patients differ markedly in infection characteristics, vascular tone, cardiac function, fluid tolerance, immune status, and organ dysfunction, so bundle completion should lead to adaptive reassessment rather than signal that treatment is finished.

To make individualized sepsis care more explicit and reproducible, the authors describe a two-level framework they call adaptive precision medicine. The first level is the standardized safety component: essential early interventions that should not be held up by further phenotyping. The second is an adaptive adjustment layer, in which the selection, titration, reevaluation, de-escalation, or discontinuation of treatment is guided by evolving physiological, biological, and microbiological information. Together, the two layers form a continuous closed-loop system linking standardized initial management with interpretation of the patient’s condition, treatment adjustments, efficacy assessment, and reevaluation. Importantly, the authors stress that the framework primarily reorganizes individualized practices already present in current sepsis guidelines, rather than proposing new treatment targets or a separate set of algorithms.

The commentary illustrates the framework across three therapeutic domains chosen for their different levels of evidence maturity: antimicrobial therapy, hemodynamic management, and immune-directed treatment. In antimicrobial therapy, the standardized safety component means promptly starting empirical antibiotics based on the probability of infection and the presence or absence of shock, while collecting microbiological specimens as early as possible and assessing source control. Unless doing so would cause a clinically significant delay, blood cultures and other appropriate specimens should be collected before antibiotics are administered, an approach designed to avoid delaying early effective treatment while awaiting complete microbiological results.

Once that safety foundation is established, management enters the adaptive phase. As microbiological results, the infection source, resistance risk, individual pharmacokinetic variation, the adequacy of source control, and clinical efficacy become clearer, clinicians can adjust the type of antimicrobial agent, its spectrum, route of administration, drug exposure levels, duration, and de-escalation strategy. As uncertainty decreases, the breadth of coverage can be narrowed, dosing optimized, and antibiotics stopped at the appropriate time. The authors point to recent clinical trials of extended infusion of beta-lactam antibiotics and therapeutic drug monitoring as evidence that precision antimicrobial stewardship extends well beyond the initial decision to start empirical therapy. Early effective treatment provides the floor; refinement based on accumulating information forms the adaptive component.

Hemodynamic management follows the same logic. The standardized safety component is early recognition of circulatory failure and tissue hypoperfusion, prompt initiation of stabilization, and timely use of vasoactive support when persistent hypotension is present, with the immediate aim of preventing ongoing hypoperfusion from causing further organ injury. Basic resuscitation should not be delayed while waiting for a detailed hemodynamic phenotype. After stabilization, decisions about additional fluid, vasopressor titration, inotropes, and de-resuscitation should be guided by fluid responsiveness, vascular tone, cardiac function, tissue edema or venous congestion, and organ perfusion. The authors cite the CLOVERS trial, in which an early restrictive fluid strategy did not significantly reduce mortality compared with a liberal strategy, as highlighting the difficulty of defining a single fluid strategy optimal for all patients in a highly heterogeneous population. They also cite ANDROMEDA-SHOCK-2, which combined capillary refill time with physiological assessment to individualize fluids, vasoactive therapy, and inotropic support, as more direct proof of concept for tailoring resuscitation.

Immune phenotyping, by contrast, sits in an area where the adaptive layer is far less mature. At present, the standardized safety component remains evidence-based treatment according to established clinical indications, and routine care should not be delayed while waiting for immune phenotyping or molecular testing. Corticosteroids, for example, are currently used on the basis of the clinical context of septic shock rather than prospectively validated molecular biomarkers, so immune phenotyping cannot yet replace established clinical criteria or serve as a prerequisite for starting standard treatment. The randomized ImmunoSep trial provides prospective proof-of-concept: patients with hyperinflammatory or immunoparalysis phenotypes were assigned different immune-directed interventions, which improved a prespecified organ dysfunction response but did not significantly reduce 28-day mortality. That study moved endotype-guided treatment from biological rationale into prospective clinical testing, though the evidence remains insufficient to support biomarker-guided allocation of immune therapy as routine practice.

Translational maturity also varies across the three domains. Bedside physiological parameter monitoring currently has the highest maturity: it can be completed rapidly, repeated often, and provides direct evidence to guide treatment. Microbiological and pharmacokinetic results can already guide antimicrobial adjustments in certain specific clinical scenarios. Biomarker-guided immunotherapeutic interventions have entered prospective clinical evaluation, but limited access to testing and unclear clinical benefits currently restrict their application. Multi-omics and advanced artificial intelligence, the authors conclude, are not yet sufficiently mature for treatment allocation, with reproducibility, turnaround time, infrastructure requirements, and prospective clinical utility remaining major barriers. Bedside physiological assessments and routine microbiological testing suit the vast majority of clinical scenarios, whereas immunophenotyping, transcriptomics, and advanced digital systems require additional laboratory and computational resources.

On artificial intelligence and multi-omics, the commentary takes a deliberately cautious position, describing them as enabling technologies rather than separate therapeutic modules. Reproducible transcriptomic subtypes may improve biological stratification and trial enrichment, but prospective treatment allocation based on such subtypes has not yet been established. Artificial intelligence may help integrate longitudinal physiological and laboratory data, identify changes in patient phenotype, and track treatment response to support clinical reassessment, and recent clinical studies suggest potential value in earlier recognition and treatment initiation. Even so, external validation, workflow integration, calibration, and a clear definition of clinician responsibility remain necessary before widespread implementation.

The authors also outline how reassessment bridges the two layers of their framework. Time-based checkpoints are helpful for deciding when to review treatment, but they are not rigid deadlines. In the first one to three hours, reassessment should focus on diagnostic accuracy, antimicrobial appropriateness, and improvement in perfusion. At around six hours, persistent shock, source control, cumulative fluid exposure, and organ-support needs become more important. Beyond twenty-four hours, priorities may shift toward antimicrobial de-escalation, de-resuscitation, treatment toxicity, and withdrawal of unnecessary support. Reassessment should also be triggered by clinical events, including failure of perfusion to improve after substantial fluid administration, increasing vasopressor requirements, recurrent hypoperfusion, new microbiological results, completion of source control, worsening respiratory status, or new organ injury. A patient who is no longer fluid responsive but remains hypotensive and is developing progressive congestion, for instance, should prompt reconsideration of further fluid and greater emphasis on vasoactive or cardiac support, while identification of a susceptible pathogen after adequate source control should prompt spectrum narrowing and reassessment of treatment duration. The authors are careful to note that such examples do not define a universal clinical algorithm.

In closing, the commentary argues that sepsis bundles remain essential for the reliable delivery of time-sensitive care, but that their main role is to establish a common standardized safety starting point. Recent physiology-guided and biomarker-guided trials suggest parts of the adaptive approach are becoming prospectively testable, even though the evidence remains insufficient to support a universal precision-treatment algorithm. Open questions include which patient phenotypes are sufficiently reproducible, which reassessment triggers can improve clinical outcomes, and which molecular or digital tools add value beyond high-quality bedside assessment. The authors present adaptive precision medicine as a testable framework for organizing sepsis care, one that preserves a standardized safety floor while providing a clearer, more reproducible basis for subsequent treatment adjustment, without replacing current guidelines or clinical judgment.

Subject of Research: A proposed framework positioning sepsis bundles as a standardized safety floor followed by adaptive, individualized precision care

Article Title: Sepsis bundles as a standardized safety floor: toward adaptive precision care

Article References: Zhang, Y., Chen, R., Wu, Y., Li, R., Zhang, W., & Liu, H. (2026). Sepsis bundles as a standardized safety floor: toward adaptive precision care. Anesthesiology and Perioperative Science, 4(1), Article 53. https://doi.org/10.1007/s44254-026-00200-2

Image Credits: AI Generated

DOI: 10.1007/s44254-026-00200-2

Keywords: sepsis, sepsis bundles, Surviving Sepsis Campaign, adaptive precision medicine, antimicrobial stewardship, hemodynamic management, immune phenotyping, fluid resuscitation, reassessment, multi-omics, artificial intelligence, critical care